Exabis Library
Welcome to the e-CCO Library!
P546: Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P546: The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P546: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P547 Inadequate vitamin C status and association with inflammatory biomarkers in adults with active Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P547: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P547: Distribution of mesenteric macrophage polarisation: a guide for surgical resections in Crohn’s disease?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P547: Is there an association between bariatric surgery and Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P547: Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P548: Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P548: External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P548: Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM